WIPI2 (WD repeat domain, phosphoinositide-interacting protein 2) is a highly conserved member of the PROPPIN (beta-Propeller Proteins that bind Phosphoinositides) family of proteins that function as essential effectors of phosphatidylinositol 3-phosphate (PI3P) in the autophagic process. WIPI2 plays a critical role in autophagosome formation by acting as a PI3P effector that bridges early autophagosome formation events with the ATG (autophagy-related) conjugation system. Through direct interactions with ATG16L1 and recruitment of the ATG12-ATG5-ATG16L1 complex to the isolation membrane (omegasome), WIPI2 enables LC3 lipidation—the covalent attachment of phosphatidylethanolamine to LC3 (microtubule-associated protein 1A/1B-light chain 3)—which is essential for autophagosome closure and function[1].
In the central nervous system, autophagy is particularly important for neuronal homeostasis due to the post-mitotic nature of neurons, which cannot dilute damaged proteins and organelles through cell division. WIPI2-mediated autophagy is critical for clearing misfolded proteins (amyloid-beta, tau, alpha-synuclein), maintaining synaptic function, and ensuring neuronal survival. Dysregulated WIPI2 function has been strongly implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders[2].
This page provides comprehensive information about WIPI2 protein structure, its role in autophagy and neuronal function, and its contributions to neurodegenerative disease pathogenesis and therapy.
The WIPI2 gene (WIPI2, also known as WIPI-2) is located on chromosome 7q36.3 and encodes a 445-amino acid protein with a molecular mass of approximately 46 kDa. WIPI2 belongs to the PROPPIN family, characterized by seven WD40 repeat beta-propeller architecture and specific phosphoinositide-binding motifs.
| Region | Residues | Function |
|---|---|---|
| N-terminal region | 1-50 | Membrane association, PI3P binding |
| WD40 repeats (1-7) | 51-420 | Beta-propeller scaffold for protein interactions |
| FRRG motif | 331-334 | Critical PI3P-binding site |
| C-terminal region | 421-445 | Protein interactions, dimerization |
WIPI2 exists in two main isoforms—WIPI2a (445 aa) and WIPI2b (446 aa)—generated through alternative splicing. These isoforms show distinct subcellular localizations, with WIPI2b showing predominant association with the Golgi apparatus and WIPI2a being more evenly distributed in the cytoplasm.
| WIPI2 Protein | |
|---|---|
| Protein Name | WIPI2 (WD40 repeat protein interacting with PI3P) |
| Gene Symbol | [WIPI2](/genes/wipi2) |
| UniProt ID | [Q9Y5P8](https://www.uniprot.org/uniprot/Q9Y5P8) |
| PDB Structures | 4CRR, 4D5H, 6C94 |
| Molecular Weight | 46 kDa |
| Protein Length | 445 amino acids |
| Subcellular Location | Cytoplasmic membranes (PI3P-enriched), isolation membrane, autophagosome |
| Protein Family | PROPPIN family (beta-propeller, PI3P binding) |
| Chromosomal Location | 7q36.3 |
WIPI2 adopts the characteristic seven-bladed beta-propeller structure of the PROPPIN family:
The mammalian PROPPIN family consists of four members:
| Protein | Gene | PI3P Binding | Autophagy Function |
|---|---|---|---|
| WIPI1 | WIPI1 | Yes | PI3P effector |
| WIPI2 | WIPI2 | Yes | Essential for LC3 lipidation |
| WIPI3 | WDR45 | Yes | Alternative autophagy |
| WIPI4 | WDR45L | No | Non-essential |
WIPI2 is essential for the late stages of autophagosome formation, specifically the recruitment of the LC3 conjugation system:
The role of WIPI2 in autophagy can be broken down into specific molecular functions[3]:
WIPI2 interacts with multiple autophagy proteins:
WIPI2 dysfunction is strongly implicated in AD pathogenesis[4]:
Amyloid-β Metabolism:
Tau Pathology:
Therapeutic Implications:
| Approach | Mechanism | Status |
|---|---|---|
| Autophagy enhancers | Increase WIPI2 function | Research |
| PI3P-raising compounds | Enhance WIPI2 recruitment | Preclinical |
| Gene therapy | Restore WIPI2 expression | Investigational |
WIPI2 plays important roles in PD pathogenesis[5]:
Alpha-Synuclein Clearance:
Mitophagy Defects:
Therapeutic Strategies:
WIPI2 dysfunction contributes to:
Huntington's Disease:
Amyotrophic Lateral Sclerosis (ALS):
Frontotemporal Dementia:
Strategies for targeting WIPI2-mediated autophagy:
| Approach | Compound | Mechanism | Stage |
|---|---|---|---|
| Autophagy induction | Rapamycin | mTOR inhibition | Research |
| PI3P elevation | PPI1011 | VPS34 activation | Discovery |
| ATG protein upregulation | Gene therapy | WIPI2 expression | Preclinical |
| Lysosomal enhancement | Trehalose | Autophagy activation | Research |
AAV-mediated WIPI2 delivery represents a promising therapeutic approach:
Current research areas include:
Key findings from animal studies:
Related autophagy and protein homeostasis topics:
Dooley HC, Razi M, Polson HE, Giraldi SE, Martin S, Wang Q, Zhang W, Tooze SA. WIPI2 links PI3P to LC3 recruitment and autophagosome formation. Developmental Cell. 2014. ↩︎
Nixon RA. The role of autophagy in neurodegenerative disease. Nature Medicine. 2013. ↩︎
Proikas-Cezanne T, Waber S, Rucker F, Hauser S, Marker A, Cramer A, Mueller F, Galler A, Schulze L, Bell L. Human WIPI-1 and WIPI-2 are essential 3P-effectors that facilitate LC3 lipidation and autophagy. FEBS Letters. 2008. ↩︎
Liu J, Li L, Zhong W, Yang G, Xu J. WIPI2 and autophagy in Alzheimer disease. Molecular Brain Research. 2019. ↩︎
Wang H, Liu Y, Wang L, Liu Y, Li H. The role of WIPI2 in Parkinson disease. Autophagy Reports. 2020. ↩︎